Decoy Therapeutics Inc. (DCOY): M&A transaction — Salarius completes acquisition of Decoy Therapeutics, raises ~$6.3M in public offering

Decoy Therapeutics Inc.

Closed merger with Decoy Therapeutics on Nov 12; issued Series A/B Preferred Stock convertible at 2,800:1 ratio post-anti-dilution adjustment.
Public offering priced at $1.50/unit (common + Series A/B warrants); net proceeds ~$6.3M, closed Nov 12.
Frederick Pierce (Decoy CEO) appointed CEO, replacing Mark Rosenblum who remains CFO; Dr. Barbara Hibner as CSO, Peter Marschel as CBO.
Board change: Pierce appointed Class II director; Bruce McCreedy resigned, not due to any disagreement.
Warrants: Series A (5-yr term, $1.50 exercise), Series B (1-yr term, $1.50), Pre-funded ($0.0001). Representative warrants also issued.

item 1.01 item 2.01 item 3.02 item 3.03 item 5.03 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Decoy Therapeutics Inc. completed an acquisition involving Decoy Therapeutics for 877.709 shares of Series A Non-Voting Convertible Preferred Stock and 796.306 shares of Series B Non-Voting Convertible Preferred Stock (closed 2025-11-12).

Action: acquisition
Counterparty: Decoy Therapeutics
Consideration: 877.709 shares of Series A Non-Voting Convertible Preferred Stock and 796.306 shares of Series B Non-Voting Convertible Preferred Stock
Closing: 2025-11-12

Exact text from the filing

with and into Merger Sub I (the “Merger”), resulting in the Decoy business becoming a wholly owned subsidiary of the Company. In connection with the Merger, the Company issued 877.709 shares of Series A Non-Voting Convertible Preferred Stock (the "Series A Stock") and 796.306 shares of Series B Non-Voting Convertible Preferred Stock (the "Series B Stock") to

View on SEC.gov

21 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-25-000162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.